Chronic obstructive pulmonary disease (COPD) remains a major public health problem. It is
the fourth leading cause of chronic morbidity and mortality in the United States, and is …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Significant heterogeneity of clinical presentation and disease progression exists within
chronic obstructive pulmonary disease (COPD). Although FEV 1 inadequately describes this …

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and
mortality and represents a substantial economic and social burden throughout the world. It is …

BACKGROUND: In 1995, the Global Initiative for Asthma (GINA) guidelines recommended
goals for the management of asthma, which were updated in 2002. However, there are no …

Background In some patients with chronic obstructive pulmonary disease (COPD), type 2
inflammation may increase exacerbation risk and may be indicated by elevated blood …

Background The phosphodiesterase-4 inhibitor roflumilast can improve lung function and
prevent exacerbations in certain patients with chronic obstructive pulmonary disease (COPD). …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Asthma is a global health problem affecting around 300 million individuals of all ages, ethnic
groups and countries. It is estimated that around 250,000 people die prematurely each year …